<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tiblj</journal-id><journal-title-group><journal-title xml:lang="ru">Туберкулез и болезни легких</journal-title><trans-title-group xml:lang="en"><trans-title>Tuberculosis and Lung Diseases</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-1230</issn><issn pub-type="epub">2542-1506</issn><publisher><publisher-name>Медицинские знания и технологии</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21292/2075-1230-2020-98-1-22-26</article-id><article-id custom-type="elpub" pub-id-type="custom">tiblj-1383</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Системный цитокиновый потенциал у больных с хронической обструктивной болезнью легких, завершивших лечение туберкулеза легких</article-title><trans-title-group xml:lang="en"><trans-title>Systemic cytokine potential in patients with chronic obstructive pulmonary disease who completed treatment for pulmonary tuberculosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9573-7483</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хренов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Khrenov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хренов Александр Андреевич – доктор медицинских наук, профессор, профессор кафедры пропедевтики внутренней медицины.</p><p>295006, Республика Крым, г. Симферополь, бульвар Ленина, д. 5/7.Тел.: 8 (3652) 55-49-11.E-mail: office@ma.cfuv.ru</p><p> </p></bio><bio xml:lang="en"><p>Aleksandr A. Khrenov – Doctor of Medical Sciences, Professor, Head of Propedeutics of Internal Diseases Department.</p><p>5/7, Lenina Blv., Simferopol, Crimea, 295006Phone: +7 (3652) 55-49-11.Email: office@ma.cfuv.ru</p></bio><email xlink:type="simple">studentdoctorprofessor@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6638-1673</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федосеева</surname><given-names>В. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedoseeva</surname><given-names>V. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Федосеева Виктория Михайловна – кандидат медицинских наук, доцент, доцент кафедры пропедевтики внутренней медицины.</p><p>295006, Республика Крым, г. Симферополь, бульвар Ленина, д. 5/7.Тел.: 8 (3652) 55-49-11.E-mail: office@ma.cfuv.ru</p></bio><bio xml:lang="en"><p>Viktoria M. Fedoseeva – Candidate of Medical Sciences, Associate Professor, Associate Professor of Propedeutics of Internal Diseases Department.</p><p>5/7, Lenina Blv., Simferopol, Crimea, 295006Phone: +7 (3652) 55-49-11.Email: office@ma.cfuv.ru</p></bio><email xlink:type="simple">7victoria10@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1195-1891</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гришин</surname><given-names>М М.</given-names></name><name name-style="western" xml:lang="en"><surname>Grishin</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гришин Михаил Михайлович – врач-фтизиатр.</p><p>297577, Республика Крым, Симферопольский район, с. Пионерское, ул. Майская, 1А.Тел.: 8 (978) 723-25-95</p></bio><bio xml:lang="en"><p>Mikhail М. Grishin – phthisiatrician.</p><p>297577, Republic of Crimea, Simferopol region, Mayskaya street, 1A.Phone: +7 (978) 723-25-95</p></bio><email xlink:type="simple">grishin_mm@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинская академия им. С. И. Георгиевского ФГАОУ ВО «Крымский федеральный университет им. В. И. Вернадского» МОН РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>S.I. Georgievsky Medical Academy of V.I. Vernadsky Crimean Federal University, Russian Ministry of Education and Science</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ «Крымский Республиканский центр фтизиатрии и пульмонологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State budgetary health care institution «Crimean republican centre of Phthisiology and Pulmonology»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>11</day><month>02</month><year>2020</year></pub-date><volume>98</volume><issue>1</issue><fpage>22</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хренов А.А., Федосеева В.М., Гришин М.М., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Хренов А.А., Федосеева В.М., Гришин М.М.</copyright-holder><copyright-holder xml:lang="en">Khrenov A.A., Fedoseeva V.M., Grishin M.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.tibl-journal.com/jour/article/view/1383">https://www.tibl-journal.com/jour/article/view/1383</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: изучить состояние цитокинового потенциала (TGF-β1, TNF-α, IL-1β, IL-4) в системном кровотоке больных, успешно завершивших лечение туберкулеза легких, в зависимости от наличия у них хронической обструктивной болезни легких (ХОБЛ).</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование включено 118 больных, успешно завершивших лечение туберкулеза легких к моменту данного обследования. В 1-ю группу включено 79 больных с разными формами туберкулеза легких без ХОБЛ, во 2-ю группу ‒ 39 больных с разными формами туберкулеза легких в сочетании с ХОБЛ. Контрольная группа состояла из 24 здоровых лиц.У всех больных в системном кровотоке определяли уровни IL-1β, TNF-α и IL-4, а также активной формы TGF-β1 методом иммуноферментного анализа с использованием коммерческих тест-систем.</p></sec><sec><title>Результаты</title><p>Результаты. Установлено, что на момент успешного завершения курса лечения туберкулеза у пациентов с ХОБЛ формируются: особая Th2-ассоциированная форма иммунного дисбаланса, характеризующаяся сниженным системным уровнем TNF-α в сочетании с повышенным уровнем IL-4; повышенный риск развития и прогрессирования фиброза легких за счет высокого уровня фактора роста TGF-β1 (в сравнении с пациентами без ХОБЛ); повышенный уровень TGF-β1 (в сравнении с пациентами без ХОБЛ), создающий благоприятный эндогенный фон для рецидива туберкулеза.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>The objective</title><p>The objective: to investigate the cytokine potential (TGF-β1, TNF-α, IL-1β, IL-4) in the systemic blood circulation of patients who successfully completed treatment for pulmonary tuberculosis, depending on whether they have chronic obstructive lung disease (COPD).</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. The study included 118 patients who had successfully completed treatment for pulmonary tuberculosis by the time of the examination. Group 1 included 79 patients with different forms of pulmonary tuberculosis without COPD, Group 2 – 39 patients with different forms of pulmonary tuberculosis and concurrent COPD. The Control Group consisted of 24 healthy individuals.In all patients, the levels of IL-1β, TNF-α and IL-4, as well as the active form of TGF-β1 were tested in the systemic blood circulation using commercial ELISA test systems.</p></sec><sec><title>Results</title><p>Results. By the time of successful tuberculosis treatment completion, COPD patients were found to develop the following: a special Th2-associated form of immune imbalance characterized by the reduced systemic level of TNF-α in combination with the increased level of IL-4; the increased risk of development and progression of pulmonary fibrosis due to the high level of growth factor TGF-β1 (in comparison with patients without COPD); elevated levels of TGF-β1 (compared with patients without COPD), creating favorable endogenous conditions for tuberculosis relapse.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>цитокины</kwd><kwd>факторы роста</kwd><kwd>хроническая обструктивная болезнь легких</kwd><kwd>туберкулез легких</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cytokines</kwd><kwd>growth factors</kwd><kwd>chronic obstructive pulmonary disease</kwd><kwd>pulmonary tuberculosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Belchamber K. B. R., Donnelly L. E. Macrophage dysfunction in respiratory disease // Results Probl. Cell Differ. ‒ 2017. ‒ Vol. 62. ‒ Р. 299-313. doi: 10.1007/978-3-319-54090-0_12.</mixed-citation><mixed-citation xml:lang="en">Belchamber K.B.R., Donnelly L.E. Macrophage dysfunction in respiratory disease. Results Probl. Cell Differ., 2017, vol. 62, pp. 299-313. doi: 10.1007/978-3319-54090-0_12.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Borthwick L. A., Wynn T. A., Fisher A. J. Cytokine mediated tissue fibrosis // Biochim. Biophys. Acta. ‒ 2013. ‒ № 1832 (7). ‒ Р. 1049-1060. doi: 10.1016/j.bbadis.2012.09.014.</mixed-citation><mixed-citation xml:lang="en">Borthwick L.A., Wynn T.A., Fisher A.J. Cytokine mediated tissue fibrosis. Biochim. Biophys. Acta., 2013, no. 1832 (7), pp. 1049-1060. doi: 10.1016/j.bbadis.2012.09.014.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Broekman W., Amatngalim G. D., de Mooij-Eijk Y., Oostendorp J., Roelofs H., Taube C., Stolk J., Hiemstra P. S. TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor // Respir. Res. ‒ 2016. Vol. 17. ‒ Р. 3. doi: 10.1186/s12931-015-0316-1.</mixed-citation><mixed-citation xml:lang="en">Broekman W., Amatngalim G.D., de Mooij-Eijk Y., Oostendorp J., Roelofs H., Taube C., Stolk J., Hiemstra P.S. TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor. Respir. Res., 2016, vol. 17, pp. 3. doi: 10.1186/s12931-015-0316-1.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Caramori G, Adcock I. M., Di Stefano A., Chung K. F. Cytokine inhibition in the treatment of COPD // Int. J. Chron. Obstruct. Pulmon Dis. ‒ 2014. ‒ Vol. 9. Р. 397-412. doi: 10.2147/COPD.S42544.</mixed-citation><mixed-citation xml:lang="en">Caramori G, Adcock I.M., Di Stefano A., Chung K.F. Cytokine inhibition in the treatment of COPD. Int. J. Chron. Obstruct. Pulmon Dis., 2014, vol. 9, pp. 397-412. doi: 10.2147/COPD.S42544.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Caramori G., Di Stefano A., Casolari P., Kirkham P. A., Padovani A., Chung K. F., Papi A., Adcock I. M. Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease // Curr. Med Chem. ‒ 2013. ‒ № 20(35). ‒ Р. 4317-4349.</mixed-citation><mixed-citation xml:lang="en">Caramori G., Di Stefano A., Casolari P., Kirkham P.A., Padovani A., Chung K.F., Papi A., Adcock I.M. Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive pulmonary disease. Curr. Med. Chem., 2013, no. 20(35), pp. 4317-4349.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Domingo-Gonzalez R., Prince O., Cooper A., Khader S. A. Cytokines and chemokines in Mycobacterium tuberculosis infection // Microbiol. Spectr. 2016. ‒ 4, № 5. doi: 10.1128/microbiolspec.TBTB2-0018-2016.</mixed-citation><mixed-citation xml:lang="en">Domingo-Gonzalez R., Prince O., Cooper A., Khader S.A. Cytokines and chemokines in Mycobacterium tuberculosis infection. Microbiol. Spectr., 2016, 4, no 5. doi: 10.1128/microbiolspec.TBTB2-0018-2016.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Harris J., Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity // Clin. Exp. Immunol. ‒ 2010. ‒ № 161(1). ‒ Р. 1-9. doi: 10.1111/j.1365-2249.2010.04146.x.</mixed-citation><mixed-citation xml:lang="en">Harris J., Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol., 2010, no. 161(1), pp. 1-9. doi: 10.1111/j.1365-2249.2010.04146.x.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hossain M., Norazmi M.-N. Pattern Recognition Receptors and Cytokines in Mycobacterium tuberculosis Infection ‒ The Double-Edged Sword? // Biomed. Res. Int. ‒ 2013; 179174. doi: 10.1155/2013/179174.</mixed-citation><mixed-citation xml:lang="en">Hossain M., Norazmi M.N. Pattern Recognition Receptors and Cytokines in Mycobacterium tuberculosis Infection ‒ The Double-Edged Sword? Biomed. Res. Int., 2013, 179174. doi: 10.1155/2013/179174.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Monin L., Khader S. A. Chemokines in tuberculosis: the good, the bad and the ugly // Semin Immunol. ‒ 2014. ‒ Vol. 26, № 6. ‒ Р. 552-558. doi: 10.1016/j.smim.2014.09.004.</mixed-citation><mixed-citation xml:lang="en">Monin L., Khader S.A. Chemokines in tuberculosis: the good, the bad and the ugly. Semin Immunol., 2014, vol. 26, no. 6, pp. 552-558. doi: 10.1016/j.smim.2014.09.004.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Murugan V., Peck M. J. Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease // Exp. Lung. Res. ‒ 2009. ‒ Vol. 35, № 6. ‒ Р. 439-485.</mixed-citation><mixed-citation xml:lang="en">Murugan V., Peck M.J. Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease. Exp. Lung. Res., 2009, vol. 35, no. 6, pp. 439-485.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Niedźwiedź A., Borowicz H., Kubiak K., Nicpoń J., Skrzypczak P., Jaworski Z., Cegielski M., Nicpoń J. Evaluation of serum cytokine levels in recurrent airway obstruction // Pol. J. Vet. Sci. ‒ 2016. ‒ Vol. 19, № 4. ‒ Р. 785-791. doi: 10.1515/pjvs-2016-0099.</mixed-citation><mixed-citation xml:lang="en">Niedźwiedź A., Borowicz H., Kubiak K., Nicpoń J., Skrzypczak P., Jaworski Z., Cegielski M., Nicpoń J. Evaluation of serum cytokine levels in recurrent airway obstruction. Pol. J. Vet. Sci., 2016, vol. 19, no. 4, pp. 785-791. doi: 10.1515/pjvs-2016-0099.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sichelstiel A., Yadava K., Trompette A., Salami O., Iwakura Y., Nicod L. P., Marsland B. J. Targeting IL-1β and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation // PLoS One. 2014. ‒ Vol. 9, № 2. ‒ Р. e98440. doi: 10.1371/journal.pone.0098440.</mixed-citation><mixed-citation xml:lang="en">Sichelstiel A., Yadava K., Trompette A., Salami O., Iwakura Y., Nicod L.P., Marsland B.J. Targeting IL-1β and IL-17A driven inflammation during influenza-induced exacerbations of chronic lung inflammation. PLoS One, 2014, vol. 9, no. 2, pp. e98440. doi: 10.1371/journal.pone.0098440.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Slight S. R., Khader S. A. Chemokines shape the immune responses to tuberculosis // Cytokine Growth Factor Rev. ‒ 2013. ‒ Vol. 24, № 2. Р. 105-113. doi: 10.1016/j.cytogfr.2012.10.002.</mixed-citation><mixed-citation xml:lang="en">Slight S.R., Khader S.A. Chemokines shape the immune responses to tuberculosis. Cytokine Growth Factor Rev., 2013, vol. 24, no. 2, pp. 105-113. doi: 10.1016/j.cytogfr.2012.10.002.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Su W. L., Perng W. C., Huang C. H., Yang C. Y., Wu C. P., Chen J. H. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis // Clin. Vaccine Immunol. ‒ 2010. Vol. 17, № 2. ‒ Р. 223-231. doi: 10.1128/CVI.00381-09.</mixed-citation><mixed-citation xml:lang="en">Su W.L., Perng W.C., Huang C.H., Yang C.Y., Wu C.P., Chen J.H. Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis. Clin. Vaccine Immunol., 2010, vol. 17, no. 2, pp. 223-231. doi: 10.1128/CVI.00381-09.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Won E. J., Choi J. H., Cho Y. N., Jin H. M., Kee H. J., Park Y. W., Kwon Y. S., Kee S. J. Biomarkers for discrimination between latent tuberculosis infection and active tuberculosis disease // Infect. ‒ 2017. ‒ Vol. 74, № 3. ‒ Р. 281-293. doi: 10.1016/j.jinf.2016.11.010.</mixed-citation><mixed-citation xml:lang="en">Won E.J., Choi J.H., Cho Y.N., Jin H.M., Kee H.J., Park Y.W., Kwon Y.S., Kee S.J. Biomarkers for discrimination between latent tuberculosis infection and active tuberculosis disease. Infect., 2017, vol. 74, no. 3, pp. 281-293. doi: 10.1016/j.jinf.2016.11.010.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
